Study: Copanlisib + rituximab slows relapsed indolent lymphoma
Copanlisib plus rituximab (C+R) reduces disease progression or death in patients with relapsed indolent non-Hodgkin lymphoma (iNHL), according to a …
Home ยป
Combo Shows ‘Impressive’ Survival Results in First-Line RCC
The combination of lenvatinib and pembrolizumab outperforms sunitinib as first-line therapy for advanced clear-cell renal cell carcinoma (RCC), based on …
Rituximab Likely Well-Tolerated in Pediatric Patients, but Infections Are Common
NEW YORK (Reuters Health) – Rituximab seemed to be well tolerated in children and adolescents in a retrospective study, but …